Quantbot Technologies LP Acquires Shares of 25,954 Inspire Medical Systems, Inc. $INSP

Quantbot Technologies LP bought a new position in Inspire Medical Systems, Inc. (NYSE:INSP) in the second quarter, HoldingsChannel reports. The fund bought 25,954 shares of the company’s stock, valued at approximately $1,158,000.

A number of other institutional investors also recently modified their holdings of INSP. Alberta Investment Management Corp purchased a new stake in shares of Inspire Medical Systems during the second quarter worth $5,483,000. Assenagon Asset Management S.A. boosted its position in Inspire Medical Systems by 66.2% during the second quarter. Assenagon Asset Management S.A. now owns 864,395 shares of the company’s stock valued at $38,561,000 after purchasing an additional 344,221 shares during the last quarter. Bank of Nova Scotia grew its stake in Inspire Medical Systems by 49.8% in the first quarter. Bank of Nova Scotia now owns 60,000 shares of the company’s stock valued at $3,095,000 after purchasing an additional 19,958 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Inspire Medical Systems in the second quarter valued at about $820,000. Finally, Empowered Funds LLC purchased a new stake in shares of Inspire Medical Systems during the 1st quarter worth about $1,799,000. Institutional investors and hedge funds own 94.91% of the company’s stock.

Insiders Place Their Bets

In related news, insider Jason P. Kelly sold 963 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the sale, the insider directly owned 18,985 shares in the company, valued at approximately $1,130,556.75. The trade was a 4.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 2.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on INSP shares. Bank of America lowered Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 price target for the company. in a report on Friday, May 22nd. KeyCorp reaffirmed a “sector weight” rating on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Freedom Capital upgraded shares of Inspire Medical Systems to a “strong-buy” rating in a research note on Tuesday, June 30th. Robert W. Baird lifted their target price on shares of Inspire Medical Systems from $54.00 to $59.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. Finally, Truist Financial reissued a “hold” rating and issued a $62.00 target price (up from $54.00) on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, Inspire Medical Systems currently has an average rating of “Hold” and an average target price of $66.19.

Inspire Medical Systems Price Performance

NYSE INSP opened at $61.23 on Wednesday. Inspire Medical Systems, Inc. has a fifty-two week low of $38.91 and a fifty-two week high of $147.03. The stock’s 50-day moving average is $51.95 and its two-hundred day moving average is $52.50. The firm has a market cap of $1.77 billion, a P/E ratio of 13.25, a price-to-earnings-growth ratio of 4.67 and a beta of 0.70.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.38. The company had revenue of $200.58 million during the quarter, compared to the consensus estimate of $194.72 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The firm’s revenue was down 7.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, equities analysts expect that Inspire Medical Systems, Inc. will post 1.24 EPS for the current year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.